New hope for spinal cord injury: first human test of cell delivery device
Disease control
Recruiting now
This early-stage study is testing the safety of a new device designed to deliver a cell therapy called LCTOPC1 directly to the spinal cord. It will enroll 10 people with recent (21-42 days) or older (1-5 years) spinal cord injuries in the neck or upper back. The main goal is to s…
Phase: PHASE1 • Sponsor: Lineage Cell Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC